Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 185 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Serplulimab with chemotherapy for treating previously untreated extensive stage small-cell lung cancer	Serplulimab (HLX10)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2023	View \| Download
Semaglutide for treating overweight or obesity with cardiovascular disease	Semaglutide (Ozempic)	Cardiovascular disease (CVD) , Obesity	Cardiovascular System , Endocrine Nutritional and Metabolic Disorders	2023	View \| Download
Semaglutide for non-cirrhotic non-alcoholic steatohepatitis	Semaglutide (Ozempic)	Non-alcoholic steatohepatitis (NASH)	Hepatology	2023	View \| Download
Selumetinib for treating symptomatic, inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in adults	Selumetinib (AZD6244; ARRY-142886)	Plexiform neurofibromas	Neurological Cancer , Neurology	2023	View \| Download
Selpercatinib for treating advanced solid tumours with RET gene fusion in people aged 12 years and older	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Sebetralstat for treating hereditary angioedema	Sebetralstat (KVD-900)	Hereditary angioedema (HAE)	Genetic Disorders , Immunology	2023	View \| Download
Sarilumab for treating Polyarticular-course Juvenile idiopathic arthritis in children and adolescents	Sarilumab	Juvenile idiopathic arthritis	Rheumatology	2023	View \| Download
SAR443820 for treating amyotrophic lateral sclerosis (ALS)	SAR443820 (DNL788)	Amyotrophic lateral sclerosis	Neurology	2023	View \| Download
Sacituzumab govitecan for treating previously untreated locally advanced or metastatic triple negative breast cancer with negative PD-L1 status	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Breast cancer	Breast Cancer	2023	View \| Download
Sacituzumab govitecan for previously treated advanced non-small cell lung cancer	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download